Hospital Universitario Puerta de Hierro -ko ikertzaileekin lankidetzan egindako argitalpenak (21)

2023

  1. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

    Cancers, Vol. 15, Núm. 5

2021

  1. Risk factors and mortality of COVID-19 in patients with lymphoma: A multicenter study

    HemaSphere, Vol. 5, Núm. 3, pp. 1-8

2020

  1. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study

    Journal of Hematology and Oncology, Vol. 13, Núm. 1

2018

  1. Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes

    European Journal of Haematology, Vol. 101, Núm. 3, pp. 332-339

2017

  1. Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML

    Bone Marrow Transplantation, Vol. 52, Núm. 8, pp. 1138-1143

  2. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

  3. Single umbilical cord blood with or without CD341 cells from a third-party donor in adults with leukemia

    Blood Advances, Vol. 1, Núm. 15, pp. 1047-1055

2015

  1. Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts

    Annals of Hematology, Vol. 94, Núm. 4, pp. 565-573

2014

  1. Haplo-cord transplantation using CD34+ cells from a third-party donor to speed engraftment in high-risk patients with hematologic disorders

    Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 12, pp. 2015-2022

2010

  1. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia

    Annals of Hematology, Vol. 89, Núm. 11, pp. 1073-1080

2006

  1. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients [14]

    Leukemia

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051

1999

  1. Apparent cure of Graves-Basedow disease after sibling allogeneic bone marrow transplantation

    Clinical Endocrinology, Vol. 50, Núm. 2, pp. 267-270

1998

  1. Autologous peripheral blood stem cell transplantation for multiple myeloma: A report of 259 cases from the Spanish Registry

    Bone Marrow Transplantation, Vol. 21, Núm. 2, pp. 133-140

  2. Conventional cytogenetics and FISH evaluation of chimerism after sex- mismatched bone marrow transplantation (BMT) and donor leukocyte infusion (DLI)

    Haematologica, Vol. 83, Núm. 5, pp. 408-415

1997

  1. Dynamics of Sau3A in situ digestion of human chromosomes analyzed with computerized imaging

    Genome, Vol. 40, Núm. 1, pp. 123-126

1996

  1. Donor leukocyte infusions for treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation

    Bone Marrow Transplantation, Vol. 17, Núm. 3, pp. 439-441

  2. Improving chimaerism quantification in bone marrow transplant recipients by image processing and analysis after restriction endonuclease in situ digestion (IPA-REISD)

    Leukemia, Vol. 10, Núm. 7, pp. 1232-1236

  3. Restriction endonuclease in situ digestion (REISD) and fluorescence in situ hybridization (FISH) as complementary methods to analyze chimerism and residual disease after bone marrow transplantation

    Cancer Genetics and Cytogenetics, Vol. 89, Núm. 2, pp. 141-145

1992

  1. Aplastic anaemia and cvanamide

    European Journal of Haematology